IDEXX Laboratories Inc (IDXX)

IDEXX Laboratories Inc is a healthcare equipment and supplies company listed on NASDAQ as common stock under the ticker IDXX. The company develops, manufactures, and distributes diagnostics and related products for companion animals, livestock and poultry, dairy, and water testing markets in the United States and internationally. Its operations are organized into three segments: Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy.

The company’s companion animal portfolio includes point-of-care diagnostic systems, blood and urine chemistry analyzers, hematology and immunoassay instruments, urinalysis and cytology tools, coagulation analyzers, and SNAP rapid test kits. IDEXX also provides reference laboratory testing, veterinary consulting, telemedicine, imaging-related advisory services, and software for veterinary clinics and corporate groups. In water testing, it offers products designed to detect total coliforms and E. coli, along with related instruments and consumables. The company also serves livestock and poultry customers with diagnostic tests, services, and instrumentation, and markets its products through direct sales, customer service, technical support, distributors, and resellers. IDEXX was incorporated in 1983 and is headquartered in Westbrook, Maine.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-IDXX
$522.60
-6.7% Downside
Fair
$698
24.6% Upside
Undervalued
Great
0.0%
38.7x
27.4x
9.7x
44.147 B
45.047 B
2.4%
99.6%
21.1
110.1%
Valuation • Fair Value

IDEXX Laboratories Inc (NASDAQ-IDXX) Fair Value by Valuation Model

Review the available estimates for IDEXX Laboratories Inc (NASDAQ-IDXX), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$522.60

Estimated downside of 6.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$509.56

Discounted cash flow valuation reference.

Ben Graham Formula Value

$160.51

Classic Ben Graham valuation formula reference.

Comps Fair Value

$535.63

Comparable-company valuation reference.

Analyst Price Target

$698

Analysts imply upside of 24.6%.

How to read these valuation models

Use the 6 available valuation references for IDEXX Laboratories Inc (NASDAQ-IDXX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for IDEXX Laboratories Inc (NASDAQ-IDXX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

4.553 B

Current operating scale indicator.

Revenue Forecast

4.722 B

Forward revenue estimate.

EBITDA

1.622 B

Current operating profitability reference.

EBITDA Forecast

1.683 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review IDEXX Laboratories Inc (NASDAQ-IDXX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for IDEXX Laboratories Inc (NASDAQ-IDXX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

9

Relatively strong quality score.

Beneish M-Score

-2.70

No elevated caution signal from this screen.

Altman Z-Score

21.1

Relatively strong balance-sheet zone.

FCF / Net Income

110.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for IDEXX Laboratories Inc (NASDAQ-IDXX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for IDEXX Laboratories Inc (NASDAQ-IDXX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for IDEXX Laboratories Inc (NASDAQ-IDXX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

IDEXX Laboratories Inc (NASDAQ-IDXX) Stock Forecast & Technical Outlook

Review IDEXX Laboratories Inc (NASDAQ-IDXX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for IDEXX Laboratories Inc (NASDAQ-IDXX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for IDEXX Laboratories Inc (NASDAQ-IDXX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for IDEXX Laboratories Inc (NASDAQ-IDXX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for IDEXX Laboratories Inc (NASDAQ-IDXX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for IDEXX Laboratories Inc (NASDAQ-IDXX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for IDEXX Laboratories Inc (NASDAQ-IDXX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, IDEXX Laboratories Inc (NASDAQ-IDXX) has a Buy consensus, with 5 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 4
Sell 0
FAQ • Fast Investor Answers

IDEXX Laboratories Inc (NASDAQ-IDXX) Stock FAQ

Data-supported answers about IDEXX Laboratories Inc (NASDAQ-IDXX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$522.60
Estimated downside 6.7%
Valuation Rating
Overvalued
Estimated downside of 6.7%
Analyst Target
$698
Implied upside 24.6%
Financial Health
Great
Current financial-health read

The current fair value estimate for IDEXX Laboratories Inc (NASDAQ-IDXX) is $522.60. This implies an estimated downside of 6.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.7% versus the current market price.

The available analyst price target for IDEXX Laboratories Inc (NASDAQ-IDXX) is $698. The analyst target implies estimated upside of 24.6%.

The current financial health read for IDEXX Laboratories Inc (NASDAQ-IDXX) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for IDEXX Laboratories Inc (NASDAQ-IDXX).

The current P/E ratio listed for IDEXX Laboratories Inc (NASDAQ-IDXX) is 38.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for IDEXX Laboratories Inc is 44.147 B.

The current enterprise value listed for IDEXX Laboratories Inc is 45.047 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for IDEXX Laboratories Inc is NASDAQ-IDXX, and the stock is listed on NASDAQ.

IDEXX Laboratories Inc (NASDAQ-IDXX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for IDEXX Laboratories Inc is 2.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for IDEXX Laboratories Inc is 99.6%. Free float helps investors understand how much of the share base is available for public trading.